Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27406479 | 1.00 | VNN1 (0.31) | VNN1HSD11B1LMNACYP2C9 | |
| SCHEMBL12735322 | 0.79 | SIGMAR1 (0.35) | VNN1 | |
| SCHEMBL14826541 | 0.77 | — | — | |
| SCHEMBL31621433 | 0.77 | KMT2A (0.37) | HSD11B1 | |
| SCHEMBL3478319 | 0.74 | GLB1 (0.31) | — | |
| SCHEMBL4550211 | 0.74 | SMN1; SMN2 (0.33) | HSD11B1 | |
| SCHEMBL9612720 | 0.74 | LMNA (0.38) | VNN1LMNACYP2C9 | |
| SCHEMBL9612817 | 0.74 | LMNA (0.38) | VNN1LMNACYP2C9 | |
| SCHEMBL14826533 | 0.74 | LMNA (0.38) | VNN1LMNACYP2C9 | |
| SCHEMBL2098997 | 0.74 | LMNA (0.38) | VNN1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | VNN1 460/4885HSD11B1 1658/4885LMNA 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.